- Home
- FHI vs XENE Comparison
FHI vs XENE Comparison
Compare FHI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHI | XENE |
|---|---|---|
| Founded | 1955 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.2B |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FHI | XENE |
|---|---|---|
| Price | $65.39 | $60.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $54.20 | ★ $68.55 |
| AVG Volume (30 Days) | 507.8K | ★ 612.3K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $1,102,924,000.00 | $311,000.00 |
| Revenue This Year | $9.90 | N/A |
| Revenue Next Year | $4.35 | $2,496.48 |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.66 | $35.60 |
| 52 Week High | $67.20 | $72.66 |
Technical Indicators
Market Signals| Indicator | FHI | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 64.53 | 44.39 |
| Support Level | $51.79 | $61.16 |
| Resistance Level | $67.20 | $62.91 |
| Average True Range (ATR) | 1.42 | 1.97 |
| MACD | -0.06 | -0.46 |
| Stochastic Oscillator | 64.34 | 29.47 |
Price Performance
Historical ComparisonAbout FHI Federated Hermes Inc.
Federated Hermes provides asset management services for institutional and individual investors. The firm had $907.1 billion in managed assets at the end of the first quarter of 2026, composed of equity (11%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (75%) funds. The company's cash management operations are expected to generate around 53% of Federated's revenue this year, compared with 30%, 10%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.